ConductScience.org, home

Paper10698518

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.

Newman SP and 4 others. Oncogene, 2000. Cited by 84 papers, by iCite.

Cite this record

ConductScience Library. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Papers, record 10698518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10698518

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
PubMed
Journal
Oncogene
PubMed
Year
2000
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
84
iCite
Relative citation ratio, by iCite
1.58
iCite
Revised in PubMed
2026-10-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Newman SPS P
2Bates NPN P
3Vernimmen DD
4Parker MGM G
5Hurst HCH C

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
DNA-Binding ProteinsMajor topic
EstrogensMajor topic
Gene Expression Regulation, NeoplasticMajor topic
Genes, erbB-2Major topic
IntronsMajor topic
Neoplasm ProteinsMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Receptors, EstrogenMajor topic
Transcription FactorsMajor topic
Binding Sites
Binding, Competitive
DNA Footprinting
Enhancer Elements, Genetic
Female
Histone Acetyltransferases
Humans
Ligands
Mutagenesis, Site-Directed
Nuclear Receptor Coactivator 1
Protein Binding
Protein Conformation
Proto-Oncogene Mas
Transcription Factor AP-2

Source PubMed

Download CSV of topics

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18290251Jun and Fos heterodimerize with ATFa, a member of the ATF/CREB family and modulate its transcriptional activity.Oncogene1994https://conductscience.org/library/papers/8290251PubMed
210629551Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer.J Pathol1999https://conductscience.org/library/papers/10629551PubMed
38170474Characterization of ligand-dependent phosphorylation of the estrogen receptor.Mol Endocrinol1994https://conductscience.org/library/papers/8170474PubMed
41973827Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.Oncogene1990https://conductscience.org/library/papers/1973827PubMed
57477377Requirement for neuregulin receptor erbB2 in neural and cardiac development.Nature1995https://conductscience.org/library/papers/7477377PubMed
69541193Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer.Breast Cancer Res Treat1998https://conductscience.org/library/papers/9541193PubMed
79252329AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.Science1997https://conductscience.org/library/papers/9252329PubMed
89427757Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor.EMBO J1998https://conductscience.org/library/papers/9427757PubMed
97849263Negative transcriptional regulation by nuclear receptors.Semin Cancer Biol1994https://conductscience.org/library/papers/7849263PubMed
108670870TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.EMBO J1996https://conductscience.org/library/papers/8670870PubMed
119797688ERBB2 oncogene in human breast cancer and its clinical significance.Eur J Cancer1998https://conductscience.org/library/papers/9797688PubMed
128099725Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells.Oncogene1993https://conductscience.org/library/papers/8099725PubMed
132885917erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.Science1987https://conductscience.org/library/papers/2885917PubMed
143798106Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987https://conductscience.org/library/papers/3798106PubMed
151680817Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice.Int J Cancer1991https://conductscience.org/library/papers/1680817PubMed
167737129ATF-2 contains a phosphorylation-dependent transcriptional activation domain.EMBO J1995https://conductscience.org/library/papers/7737129PubMed
178895516A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma.Oncogene1996https://conductscience.org/library/papers/8895516PubMed
189659924Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription.Mol Cell1998https://conductscience.org/library/papers/9659924PubMed
199192902A signature motif in transcriptional co-activators mediates binding to nuclear receptors.Nature1997https://conductscience.org/library/papers/9192902PubMed
209642216Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits.J Biol Chem1998https://conductscience.org/library/papers/9642216PubMed

See all 45 referencesDownload CSV of references

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.

PMIDTitleJournalYearIn PapersSource
42315983Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer.Histopathology2026https://conductscience.org/library/papers/42315983PubMed
38643188Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.World J Surg Oncol2024https://conductscience.org/library/papers/38643188PubMed
35654312Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women.Cancer Epidemiol Biomarkers Prev2022https://conductscience.org/library/papers/35654312PubMed
33920089
Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer.
Cancers (Basel)2021https://conductscience.org/library/papers/33920089PubMed
31801615Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.Breast Cancer Res2019https://conductscience.org/library/papers/31801615PubMed
29880033Membrane-bound estrogen receptor alpha initiated signaling is dynamin dependent in breast cancer cells.Eur J Med Res2018https://conductscience.org/library/papers/29880033PubMed
29880014Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.Breast Cancer Res2018https://conductscience.org/library/papers/29880014PubMed
24678732Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex.Mol Endocrinol2014https://conductscience.org/library/papers/24678732PubMed
24415978Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.Breast Care (Basel)2013https://conductscience.org/library/papers/24415978PubMed
24367183Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.Breast Cancer (Dove Med Press)2011https://conductscience.org/library/papers/24367183PubMed
23991224Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.PLoS One2013https://conductscience.org/library/papers/23991224PubMed
23821662Estrogen represses gene expression through reconfiguring chromatin structures.Nucleic Acids Res2013https://conductscience.org/library/papers/23821662PubMed
22763464A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.Breast Cancer Res Treat2012https://conductscience.org/library/papers/22763464PubMed
22703232Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.BMC Cancer2012https://conductscience.org/library/papers/22703232PubMed
22190867Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles.J Carcinog2011https://conductscience.org/library/papers/22190867PubMed
22002538Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.EMBO J2011https://conductscience.org/library/papers/22002538PubMed
21396094Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.Breast Cancer Res2011https://conductscience.org/library/papers/21396094PubMed
21204711HER2: biology, detection, and clinical implications.Arch Pathol Lab Med2011https://conductscience.org/library/papers/21204711PubMed
20887199Mechanisms of endocrine resistance in breast cancer.Annu Rev Med2011https://conductscience.org/library/papers/20887199PubMed
19917725Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM.Mol Cell Biol2010https://conductscience.org/library/papers/19917725PubMed

See all 29 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/10698518

GET https://conductscience.org/api/papers/v1/10698518/references?page=2